Biophore India receives licences from MPP to market molnupiravir

The licences are applicable for both active pharmaceutical ingredients (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32hYaot
via IFTTT